SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revolutions Medical Corp – ‘S-1’ on 4/18/14 – ‘R17’

On:  Friday, 4/18/14, at 5:15pm ET   ·   Accession #:  1437749-14-6872   ·   File #:  333-195393

Previous ‘S-1’:  ‘S-1/A’ on 7/19/13   ·   Next:  ‘S-1/A’ on 6/17/14   ·   Latest:  ‘S-1/A’ on 1/20/15

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/18/14  Revolutions Medical Corp          S-1                   63:12M                                    RDG Filings/FA

Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   2.25M 
 2: EX-23       Exhibit 23.1                                        HTML     21K 
40: R1          Document And Entity Information                     HTML     50K 
30: R2          Balance Sheets                                      HTML    106K 
38: R3          Balance Sheets (Parentheticals)                     HTML     45K 
43: R4          Statements of Operations                            HTML     90K 
58: R5          Statements of Stockholders’ Equity                  HTML    852K 
32: R6          Statements of Cash Flows                            HTML    147K 
37: R7          Note 1 - Basis of Presentation, Description of      HTML     86K 
                Business, Significant Accounting Policies,                       
                Critical Accounting Estimates and                                
                Reclassifications                                                
27: R8          Note 2 - Going Concern                              HTML     24K 
19: R9          Note 3 - Property And Equipment                     HTML     46K 
59: R10         Note 4 - Intangibles                                HTML     40K 
45: R11         Note 5 - Accounts Payable and Accrued Liabilities   HTML     47K 
44: R12         Note 7 - Payable for Indemnification                HTML     29K 
49: R13         Note 8 - Convertible Notes                          HTML    117K 
50: R14         Note 9 - Derivatives - Note Conversion Feature      HTML     74K 
48: R15         Note 10 - Commitments and Contingencies             HTML     56K 
51: R16         Note 11 - Preferred Stock and Common Stock          HTML     39K 
                Transactions                                                     
39: R17         Note 12 - Stock Options and Warrants Outstanding    HTML    118K 
42: R18         Note 13 - Related Party Transactions                HTML     42K 
47: R19         Note 14 - Subsequent Events                         HTML     24K 
63: R20         Accounting Policies, by Policy (Policies)           HTML    142K 
54: R21         Note 1 - Basis of Presentation, Description of      HTML     80K 
                Business, Significant Accounting Policies,                       
                Critical Accounting Estimates and                                
                Reclassifications (Tables)                                       
34: R22         Note 3 - Property And Equipment (Tables)            HTML     42K 
46: R23         Note 4 - Intangibles (Tables)                       HTML     34K 
36: R24         Note 5 - Accounts Payable and Accrued Liabilities   HTML     40K 
                (Tables)                                                         
14: R25         Note 8 - Convertible Notes (Tables)                 HTML     75K 
55: R26         Note 9 - Derivatives - Note Conversion Feature      HTML     78K 
                (Tables)                                                         
60: R27         Note 12 - Stock Options and Warrants Outstanding    HTML    110K 
                (Tables)                                                         
23: R28         Note 13 - Related Party Transactions (Tables)       HTML     35K 
22: R29         Note 1 - Basis of Presentation, Description of      HTML     35K 
                Business, Significant Accounting Policies,                       
                Critical Accounting Estimates and                                
                Reclassifications (Details)                                      
25: R30         Note 1 - Basis of Presentation, Description of      HTML     27K 
                Business, Significant Accounting Policies,                       
                Critical Accounting Estimates and                                
                Reclassifications (Details) - Estimated Useful                   
                Lives of Property Plant and Equipment                            
26: R31         Note 1 - Basis of Presentation, Description of      HTML     31K 
                Business, Significant Accounting Policies,                       
                Critical Accounting Estimates and                                
                Reclassifications (Details) - Fair Value, Assets                 
                and Liabilities Measured on Recurring Basis                      
28: R32         Note 2 - Going Concern (Details)                    HTML     34K 
13: R33         Note 3 - Property And Equipment (Details)           HTML     36K 
52: R34         Note 3 - Property And Equipment (Details) -         HTML     32K 
                Summary of Property And Equipment                                
33: R35         Note 4 - Intangibles (Details)                      HTML     27K 
35: R36         Note 4 - Intangibles (Details) - Summary of         HTML     28K 
                Intangible Assets                                                
17: R37         Note 5 - Accounts Payable and Accrued Liabilities   HTML     41K 
                (Details)                                                        
62: R38         Note 5 - Accounts Payable and Accrued Liabilities   HTML     41K 
                (Details) - Summary of Accounts Payable and                      
                Accrued Liabilities                                              
 9: R39         Note 7 - Payable for Indemnification (Details)      HTML     31K 
29: R40         Note 8 - Convertible Notes (Details)                HTML    296K 
57: R41         Note 8 - Convertible Notes (Details) - Notes        HTML     44K 
                Payable                                                          
16: R42         Note 8 - Convertible Notes (Details) - Notes        HTML     39K 
                Payable (Parentheticals)                                         
21: R43         Note 9 - Derivatives - Note Conversion Feature      HTML     32K 
                (Details) - Reconciliation of Derivative Liability               
24: R44         Note 9 - Derivatives - Note Conversion Feature      HTML     37K 
                (Details) - Fair Value Assumptions, Derivative                   
                Liability                                                        
31: R45         Note 10 - Commitments and Contingencies (Details)   HTML     91K 
12: R46         Note 11 - Preferred Stock and Common Stock          HTML    103K 
                Transactions (Details)                                           
18: R47         Note 12 - Stock Options and Warrants Outstanding    HTML     66K 
                (Details)                                                        
10: R48         Note 12 - Stock Options and Warrants Outstanding    HTML     72K 
                (Details) - Stock Options and Warrants Outstanding               
                Activities                                                       
56: R49         Note 13 - Related Party Transactions (Details)      HTML     47K 
15: R50         Note 13 - Related Party Transactions (Details) -    HTML     28K 
                Amounts Owed by the Company to its Executive                     
                Officers                                                         
53: R51         Note 14 - Subsequent Events (Details)               HTML     40K 
61: XML         IDEA XML File -- Filing Summary                      XML    102K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX    221K 
20: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   2.05M 
 3: EX-101.INS  XBRL Instance -- rmcp-20131231                       XML   2.11M 
 5: EX-101.CAL  XBRL Calculations -- rmcp-20131231_cal               XML     99K 
 6: EX-101.DEF  XBRL Definitions -- rmcp-20131231_def                XML    979K 
 7: EX-101.LAB  XBRL Labels -- rmcp-20131231_lab                     XML   1.47M 
 8: EX-101.PRE  XBRL Presentations -- rmcp-20131231_pre              XML    924K 
 4: EX-101.SCH  XBRL Schema -- rmcp-20131231                         XSD    238K 
41: ZIP         XBRL Zipped Folder -- 0001437749-14-006872-xbrl      Zip    190K

‘R17’   —   Note 12 – Stock Options and Warrants Outstanding

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.0.8
Note 12 - Stock Options and Warrants Outstanding
 12 Months Ended
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 12 – Stock Options and Warrants Outstanding


The Company’s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock.  The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.  The plan allows the Company to issue either stock options or common shares.


From time to time, the Company enters into consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac™ Safety Syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.


Consultants are issued options at a discount to the market price at the date of issuance. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes Model.


During 2013, under the terms of the Company’s 2007 Stock Option Plan, 3,425,000 options were issued for consulting services exercisable at $0.02~$0.50 per share. The options have a term of 10 days to one year and vest upon issuance. The aggregate fair value of these options equal to $86,066 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.10% to 0.18% (2) expected life of 0.03 to 1.06 years (3) expected volatility of 163% to 261% and (4) zero expected dividends.


The following table summarizes the stock option activity:


   

Number of

Shares

Under Option

   

Weighted-

average

Exercise

Price

   

Weighted Average Remaining Contractual Term (in years)

   

Aggregate Intrinsic Value

 

Outstanding at December 31, 2011

    15,473,750     $ 0.39       2.45       869,825  

Granted

    2,875,000       0.18       0.98          

Exercised

    (575,000

)

    0.25                  

Forfeited or expired

    (5,673,750

)

                       

Outstanding at December 31, 2012

    12,100,000       0.20       1.18       150,000  

Granted

    3,425,000       0.11       0.56          

Exercised

    (2,500,000

)

    0.05                  

Forfeited or expired

    (7,525,000

)

                       

Outstanding at December 31, 2013

    5,500,000       0.12       0.36          

At December 31, 2013, there were 6,249,008 warrants outstanding. 4,166,005 of these warrants are exercisable at $0.125 and 2,083,003 are exercisable at $0.25. The warrants exercisable at $0.125 were originally to expire on March 31, 2013, but were modified to expire on June 30, 2014. The warrants exercisable at $0.25 were originally to expire on March 31 or June 30, 2013, but were modified to expire on September 30, 2014. In addition, the exercise prices of these warrants were reduced on November 20, 2013 from $0.25 to $0.125 in the case of the $0.125 warrants and from $0.50 to $0.25 in the case of the $0.25 warrants. The Company recorded modification expense of $210,373 for the year ended December 31, 2013.


The following table summarizes the warrant activity:


   

Number of

Shares

Under Option

   

Weighted-

average

Exercise

Price

   

Weighted Average Remaining Contractual Term (in years)

   

Aggregate Intrinsic Value

 

Outstanding at December 31, 2011

    3,371,600       0.39       2.45       -  

Granted

    5,739,008       0.33       0.15          

Exercised

    (660,000

)

    0.50                  

Forfeited or expired

    (5,570,608

)

                       

Outstanding at December 31, 2012

    2,880,000     $ 0.33       0.30       -  

Granted

    9,408,015       0.33       1.3          

Exercised

    -       -                  

Forfeited or expired

    (6,039,007

)

                       

Outstanding at December 31, 2013

    6,249,008       0.17       0.34       -  

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1’ Filing    Date    Other Filings
9/30/1410-Q
6/30/1410-Q,  NT 10-Q
Filed on:4/18/14
12/31/1310-K,  NT 10-K
11/20/13
6/30/1310-Q,  10-Q/A,  NT 10-Q
3/31/1310-Q,  NT 10-Q
12/31/1210-K,  10-K/A,  NT 10-K
12/31/1110-K
 List all Filings 
↑Top
Filing Submission 0001437749-14-006872   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., May 12, 12:44:01.1pm ET